ImmusanT, Inc. Information

ImmusanT, Inc. | 760 followers on LinkedIn. ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management.

Website	http://www.immusant.com
Revenue	$6 million
Funding	$72.8 million
Employees	8 (0 on RocketReach)
Founded	2010
Address	1 Kendall Sq, Ste B2004, Cambridge, Massachusetts 02139, US
Phone	+1 617-299-8399
Technologies	Microsoft Outlook , Microsoft Exchange Online , Enom DNS Hosting (view technologies)
Industry	Biotechnology, Drug Manufacturing & Research, Research, Pharmaceuticals, Science and Engineering, Drug Discovery, Healthcare, Health Diagnostics, Health Care, Therapeutics
Web Rank	3 Million
Keywords	Immunology Research, Immune System Modulation, Immunotherapy, Autoimmune Therapies, Biotechnology, Novel Therapeutics, Pharmaceutical Research, Drug Development, Therapeutic Antibodies, Biologics, Protein Therapeutics, Clinical Trials, Digestive Health, Precision Medicine, Inflammatory Bowel Disease
Competitors	Novartis, Pfizer, Sanofi, AstraZeneca, Genentech, Amgen, Regeneron, Vertex Pharmaceuticals, Moderna Therapeutics, Receptos, a wholly-owned subsidiary of Celgene +39 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 54 Companies, NAICS Code 541711 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies